US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.15

+1.283.06%

Volume:375

Turnover:16.17K

Market Cap:32.37M

PE:- -

High:43.16

Open:43.16

Low:43.15

Close:41.87

52wk High:43.51

52wk Low:29.80

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.95

T/O Rate:0.05%

Dividend:0.14

Dividend Rate:0.33%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Natera Says Lung Cancer MRD Study Links Signatera Results to 3-Year Recurrence-Free Survival in 1,129 Patients

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Natera Inc Stock (NTRA) Moved Up by 5.05% on Sep 17: Key Drivers Unveiled

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Guardant Health on Track for Record High Close

Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma

Adaptive Biotechnologies Announces Update to Nccn Guidelines® for Multiple Myeloma, Strengthening Mrd Testing Recommendations and Specifically Referencing Clonoseq®

THOMSON REUTERS

Alert Incorrectly Tagged to Adaptive Biotechnologies Withdrawn

Adaptive Raises $30 Million Series B Led by Tidemark to Bring Agentic Accounting to Construction

THOMSON REUTERS

Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million

Genetic Signatures Faces Shareholder-Requested Vote on Director Removal

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC), Natera (NTRA) and Vertex Pharmaceuticals (VRTX)

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Cellectis pivots to in vivo gene editing and exits key CAR-T programs

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.1543,"timestamp":1789675200000,"preClose":41.8729,"halted":0,"volume":375,"delay":0,"changeRate":0.03060213168899211,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Pre-Mkt","change":1.2814,"latestTime":"09-18 08:07:46 EDT","open":43.16,"high":43.16,"low":43.1543,"amount":16172,"amplitude":0.000136,"askPrice":69.04,"askSize":200,"bidPrice":38.87,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":43.1543,"sharesOutstanding":650000,"nav":41.933,"aum":31449919.88,"dividendRate":0.0033,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.16,"preClose":43.1543,"latestTime":"16:10 EDT","volume":7,"amount":302.0915,"timestamp":1789675804724,"change":0.0057,"changeRate":0.000132,"amplitude":0},"volumeRatio":0.9484068206990622,"impliedVol":0.0896,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9484068206990622,"shares":750000,"dividePrice":0.1424,"high":43.16,"amplitude":0.000136,"preClose":41.8729,"low":43.1543,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":43.1543,"committee":-0.333333,"eps":0,"divideRate":0.0033,"volume":375,"delay":0,"ttmEps":0,"open":43.16,"prevYearClose":36.3062,"prevWeekClose":40.9874,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":41.0314,"twentyDayClose":42.8036,"sixtyDayClose":36.6303},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668421699","title":"Natera Says Lung Cancer MRD Study Links Signatera Results to 3-Year Recurrence-Free Survival in 1,129 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2668421699","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668421699?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:01","pubTimestamp":1789725664,"startTime":"0","endTime":"0","summary":"Natera says lung cancer MRD study links Signatera results to 3-year recurrence-free survival in 1,129 patientsNatera disclosed clinical data already presented at the IASLC 2026 World Conference on Lun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL4kcGf8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4139","LU0106261612.USD","NTRA","LU0345770993.USD","LU2065731478.USD","LU2065171311.SGD","LU2065169927.USD","LU1988902786.USD","LU2065171402.SGD","LU0012050646.USD","LU0963586101.USD","LU2324357040.USD","LU1064131342.USD","LU0053671581.USD","LU0345770308.USD","LU2065170008.USD","GNOM","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668990420","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265","url":"https://stock-news.laohu8.com/highlight/detail?id=2668990420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668990420?lang=en_us&edition=fundamental","pubTime":"2026-09-18 06:51","pubTimestamp":1789685462,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 1,195 shares for $32,265Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 1,195 common shares on Sep. 15","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLw809m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668976309","title":"Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300","url":"https://stock-news.laohu8.com/highlight/detail?id=2668976309","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668976309?lang=en_us&edition=fundamental","pubTime":"2026-09-18 05:10","pubTimestamp":1789679402,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa sells 116 common shares for $20,300Guardant Health director Tariq Musa sold 116 common shares on Sep. 16, 2026 at USD 175.Directly held common stock fell to 11,449 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL5VHhJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","FFOX","LFSC","BK4196","HELX","BK4585","EKG","GDOC","LU0109394709.USD","PTH","BK4551","LU0889565916.HKD","BK4588","GNOM","BK4535","LU0320765992.SGD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994618","title":"Natera Inc Stock (NTRA) Moved Up by 5.05% on Sep 17: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994618","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994618?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:15","pubTimestamp":1789672525,"startTime":"0","endTime":"0","summary":"• Natera reported strong adoption for Signatera and positive Medicare reimbursement updates.\n• The company achieved robust top-line revenue growth with $2.31B annual revenue.\n• Analysts issued Buy ratings with an average price target of $342.35.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262173862-market-movers-ntra-20260917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","LU2065169927.USD","NTRA","LU2324357040.USD","LU2065171402.SGD","LU0012050646.USD","LU2065170008.USD","LU2065731478.USD","BK4139","LU0106261612.USD","LU0345770308.USD","LU0053671581.USD","LU0345770993.USD","LU0963586101.USD","LU2264538146.SGD","LU1064131342.USD","LU1988902786.USD","GNOM","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668995985","title":"US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995985?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:20","pubTimestamp":1789658440,"startTime":"0","endTime":"0","summary":"UPDATE 6-US Health Secretary Kennedy Jr. adds eight new members to key health committeeSept 17 (Reuters)-US Health Secretary Robert F. Kennedy Jr. on Thursday named eight new members to the advisory p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4591AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","LU0320765992.SGD","GDOC","FFOX","BK4196","HELX","BK4585","LU0109394709.USD","PTH","LU0889565916.HKD","GNOM","GNMX","BK4588","BK4551","EKG","LFSC","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668998049","title":"Guardant Health on Track for Record High Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2668998049","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668998049?lang=en_us&edition=fundamental","pubTime":"2026-09-17 22:16","pubTimestamp":1789654560,"startTime":"0","endTime":"0","summary":"Guardant Health, Inc.  is currently at $180.24, up $5.34 or 3.05%--Would be new all-time closing high --Would be the first new record closing high since Feb. 12, 2021, when it closed at $179.10--On pace for largest percent increase since Sept. 15, 2026, when it rose 4.65%--Currently up three of the past four days--Up 13.34% month-to-date--Up 76.46% year-to-date--Up 206.52% from 52 weeks ago , when it closed at $58.80--Would be a new 52-week closing high--Up 212.53% from its 52-week closing low of $57.67 on Sept. 24, 2025--Traded as high as $181.50; new all-time intraday high --Up 3.77% at today's intraday highAll data as of 10:14:03 AM ETSource: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Guardant Health on Track for Record High Close","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","HELX","BK4196","GNMX","BK4551","LFSC","GDOC","BK4588","GNOM","BK4535","EKG","LU0320765992.SGD","LU0889565916.HKD","FFOX","PTH","GH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668326962","title":"Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2668326962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668326962?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:11","pubTimestamp":1789647087,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) highlighted updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Multi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-reports-update-to-nccn-guidelines-for-multiple-myeloma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-reports-update-to-nccn-guidelines-for-multiple-myeloma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668691964","title":"Adaptive Biotechnologies Announces Update to Nccn Guidelines® for Multiple Myeloma, Strengthening Mrd Testing Recommendations and Specifically Referencing Clonoseq®","url":"https://stock-news.laohu8.com/highlight/detail?id=2668691964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668691964?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:00","pubTimestamp":1789646404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA3LT1KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668969754","title":"Alert Incorrectly Tagged to Adaptive Biotechnologies Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2668969754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668969754?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:10","pubTimestamp":1789643456,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert incorrectly tagged to Adaptive Biotechnologies withdrawnAn alert from agentic accounting platform Adaptive announcing a fundraise was inadvertently tagged to publicly listed Adaptive Bi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUAC7NJCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668896968","title":"Adaptive Raises $30 Million Series B Led by Tidemark to Bring Agentic Accounting to Construction","url":"https://stock-news.laohu8.com/highlight/detail?id=2668896968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668896968?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:00","pubTimestamp":1789642803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUAC7NJCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668937970","title":"Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668937970","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668937970?lang=en_us&edition=fundamental","pubTime":"2026-09-17 09:35","pubTimestamp":1789608949,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz disposes of 89,100 common shares worth $30.15 millionMatthew Rabinowitz, executive chairman, sold Natera common stock on Sept. 14-15.Disposed of 99,900 sha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLc1ry2x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU2264538146.SGD","LU0345770993.USD","LU0106261612.USD","LU1064131342.USD","LU1988902786.USD","GNOM","BK4139","LU0012050646.USD","LU2065171311.SGD","LU0345770308.USD","LU2065169927.USD","LU2065731478.USD","LU2065171402.SGD","LU0053671581.USD","NTRA","HELX","LU2065170008.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668346869","title":"Genetic Signatures Faces Shareholder-Requested Vote on Director Removal","url":"https://stock-news.laohu8.com/highlight/detail?id=2668346869","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668346869?lang=en_us&edition=fundamental","pubTime":"2026-09-17 08:07","pubTimestamp":1789603652,"startTime":"0","endTime":"0","summary":"Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an announcement. Genetic Signatures Ltd, a molecular diagnostics firm focused on PCR-based infec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genetic-signatures-faces-shareholder-requested-vote-on-director-removal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genetic-signatures-faces-shareholder-requested-vote-on-director-removal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","HELX","BMED","HTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062145","title":"Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062145?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:02","pubTimestamp":1789498945,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the result preserves the biomarker-driven monitoring approach supporting potential demand for its Guardant","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZN","HELX","LU2089984988.USD","LU1267930573.SGD","GH","LU0432979614.USD","LU0889565916.HKD","LU0128525929.USD","LU2468319806.SGD","BK4585","LU2237443382.USD","BK4588","LU2237443549.SGD","AZNH","LU0289739699.SGD","LU0058720904.USD","LU2236285917.USD","LU0109394709.USD","PTH","EKG","BK4535","BK4007","FFOX","LU0310800379.SGD","IE00B3T34201.USD","GNOM","LU2456880835.USD","BK4551","LU0320765992.SGD","LU2417539215.USD","BK4568","LU2237443978.SGD","LU2237443465.HKD","LU0029864427.USD","GDOC","LU2237443622.USD","LU2462157665.USD","LU1829250122.USD","BK4196","GNMX","LU0708994859.HKD","LFSC","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641173","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC), Natera (NTRA) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641173?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:20","pubTimestamp":1789471221,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Centene (CNC), Natera (NTRA) and Vertex Pharmaceut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-centene-cnc-natera-ntra-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-centene-cnc-natera-ntra-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","BK4139","VERX","IDNA","LU0053671581.USD","IE00B19Z3581.USD","IE0009355771.USD","LU0128526141.USD","BBH","LU2456880835.USD","IE00B19Z9Z06.USD","XLV","NTRA","LU1035775433.USD","BK4154","LABU","LU1430594728.SGD","LU1291159041.SGD","LU1674673691.USD","LU2065171311.SGD","LU2236285917.USD","LU0823416689.USD","LU0012050646.USD","PBE","BK4581","LU2462157665.USD","VRTX","LU2065169927.USD","BK4023","HCSG","LU0289739699.SGD","XBI","LU0234570918.USD","IE0002270589.USD","LU1585245621.USD","LU0648000940.SGD","GNMX","BK4567","LU1988902786.USD","IBBQ","TBXU","BIB","BK4585","BK4137","LU0130518102.USD","LU0859254822.USD","IBB","CNC","CNCG","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GH","BK4585","LFSC","LU0109394709.USD","FFOX","HELX","GNMX","PTH","GDOC","GNOM","LU0889565916.HKD","LU0320765992.SGD","BK4196","BK4551","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667869541","title":"Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667869541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667869541?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:37","pubTimestamp":1789418272,"startTime":"0","endTime":"0","summary":"Niki BioSolutions Inc ( ($NIKI) ) just unveiled an announcement. Niki BioSolutions Inc operates in the biotechnology and molecular diagnostics sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","FWD","XT","GNMX","LNGR","JDOC","BBP","DARP","HELX","RSPH","SYNB","BK4588","IBB","IEIH","BMED","HTEC","FHLC","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","GDOC","FFOX","GH","GNMX","EKG","GNOM","BK4551","LU0889565916.HKD","HELX","LU0109394709.USD","BK4585","PTH","BK4196","LFSC","LU0320765992.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667376655","title":"Cellectis pivots to in vivo gene editing and exits key CAR-T programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2667376655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667376655?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:15","pubTimestamp":1789370144,"startTime":"0","endTime":"0","summary":"Cellectis SA ( ($FR:ALCLS) ) has provided an announcement. Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WDNA","SYNB","IDNA","HELX","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653981","title":"Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653981","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653981?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:40","pubTimestamp":1789368000,"startTime":"0","endTime":"0","summary":"Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360712/0/en/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","GNMX","IDNA","SYNB","BK4156","NC","HELX","HEAL","CLLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666508352","title":"Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666508352","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666508352?lang=en_us&edition=fundamental","pubTime":"2026-09-12 09:35","pubTimestamp":1789176943,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz disposes of USD 16.32 million in common sharesNatera Executive Chairman Matthew Rabinowitz sold 50,000 common shares on Sept. 11, 2026 at about USD 325.01 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260912:nNDL6qGymP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU0106261612.USD","LU0963586101.USD","LU2264538146.SGD","LU1988902786.USD","LU0345770993.USD","LU2065731478.USD","LU2065169927.USD","LU2324357040.USD","LU1064131342.USD","HELX","LU2065171311.SGD","NTRA","LU2065171402.SGD","BK4139","LU2065170008.USD","LU0012050646.USD","GNOM","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}